Abstract 622P
Background
CCL26 is widely found in various tissues of the human body and mainly acts on eosinophils. However, its role in tumors remains unclear. In this study, we aimed to investigate the role of CCL26 in pan-cancer.
Methods
Data were downloaded from University of California Santa Cruz (UCSC) Xena and The Cancer Genome Atlas (TCGA). The expression of CCL26 was investigated in TCGA_GTEx, TCGA and TCGA paired samples, respectively. Subsequently, Kaplan-Meier analyses were performed on 33 TCGA tumors, and clinical correlation and one-way Cox regression analyses were performed on tumors in which CCL26 affected prognosis. In addition, we selected more than 500 representative tumors of renal clear cell carcinoma (KIRC) to construct a nomogram model to confirm the prognostic value of CCL26 in the tumors. In addition, CCL26 there was an association with immune cell infiltration. Mechanistically, we performed functional enrichment analysis to explore potential signaling pathways in which CCL26 may be involved.
Results
Our study found that CCL26 expression was significantly up-regulated in 20 tumors and down-regulated in 6. High expression of CCL26 was associated with shorter overall survival (OS) in adrenocortical carcinoma (ACC), bladder uroepithelial carcinoma (BLCA), renal clear cell carcinoma (KIRC), papillary renal cell carcinoma (KIRP), and mesothelioma (MESO). CCL26 had high predictive accuracy (AUC > 0.9) for five cancers, including cholangiocarcinoma (CHOL; AUC = 0.952, CI: 0.890-0=1.000), renal smoky cell carcinoma (KICH; AUC = 0.928, CI: 0.875- 0.981), lung squamous cell carcinoma (LUSC; AUC = 0.928, CI: 0.905-0.951), skin melanoma (SKCM; AUC = 0.936, CI: NA-NA), thymoma (THYM; AUC = 0.933, CI: 0.829-1.000). -1.000).
Conclusions
CCL26 may serve as a potential prognostic biomarker and a promising target for cancer immunotherapy. It is also associated with clinical outcomes and immune microenvironment in a variety of tumors, and may influence tumor development by regulating signaling pathways of stem cell pluripotency and immune-related pathways.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract
362P - Efficacy and safety of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in head and neck squamous cell cancer (HNSCC)
Presenter: Irene Braña
Session: Poster Display
Resources:
Abstract
363P - Effect of financial distress and mental well-being of patients with early vs advanced oral cancer on informal caregiver's quality of life: A prospective real-world data from public health sector hospital
Presenter: Abhinav Thaduri
Session: Poster Display
Resources:
Abstract
364P - Artificial intelligence provides more accurately neck lymph nodes auto-segmentation in radiotherapy
Presenter: chiencheh Chen
Session: Poster Display
Resources:
Abstract
365P - Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis
Presenter: Anbarasan Anbazagan
Session: Poster Display
Resources:
Abstract
366P - Pre-treatment oral fungal microbiome and nasopharyngeal carcinoma prognosis: A population-based cohort study in southern China
Presenter: Yufeng Chen
Session: Poster Display
Resources:
Abstract
367P - Prevalence and association of sarcopenia with mortality in patients with head and neck cancer: A meta-analysis
Presenter: Claire Lim
Session: Poster Display
Resources:
Abstract
368P - Distinct gene expression profiling explored using nanostring tumor signalling 360 panel with validations in different clinical stages of oral submucous fibrosis patients: A first Indian study
Presenter: Yasasve Madhavan
Session: Poster Display
Resources:
Abstract
370P - Low-dose nivolumab with induction chemotherapy for inoperable HNSCC in 111 patients: Response rates, survival, and implications for LMICs
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
371P - The role of FDG-PET/CT in the assessment of response to radiation therapy in head and neck cancers: A systematic review and meta-analysis
Presenter: Felix Wijovi
Session: Poster Display
Resources:
Abstract